日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.

TNG260 是一种小分子 CoREST 抑制剂,可使 STK11 突变肿瘤对 PD-1 抗肿瘤免疫疗法敏感。

Ahronian Leanne G, Sahu Soumyadip, Zhang Minjie, Patel Ayushi S, Geng Ke, Bhattacharya Reshmee, Falchook Gerald S, Goldman Jonathan W, Spira Alexander I, Punekar Salman R, Spigel David R, Wang Judy S, Skoulidis Ferdinandos, Stephens Janaye, Meynardie Mary, Powell Jaylen M, Lopez Alfonso, Ranieri Michela, Ploszaj Magdalena A, Tan Yi Jer, Lee Yeuan Ting, Yu Yi, Deng Jiehui, Chen Ting, McCarren Patrick, Tsai Alice, Hussain Suleman S, Doyon Brian, Amemiya Kenjie, Ermolieff Jacques, Shahagadkar Preksha, Das Nikitha M, Flynn Lauren R, Shields Julie A, Danielczyk Laney, McMillan Brian J, Mignault Andre, Meier Samuel R, Wu Hsin-Jung, Guerin David J, Whittington Douglas A, Min Chengyin, Sienczylo Iga, Maxwell John P, DiBenedetto Heather J, Watanabe Hideo, Haines Brian B, Huang Alan, Crystal Adam, Andersen Jannik N, Wu Xinyuan, Wong Kwok-Kin

GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-MUC1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies

GT-00AxIL15,一种新型肿瘤靶向IL-15免疫细胞因子,用于治疗TA-MUC1阳性实体瘤:临床前体外和体内药效学及生物分布研究

Gellert, Johanna; Jäkel, Anika; Danielczyk, Antje; Goletz, Christoph; Lischke, Timo; Flechner, Anke; Dix, Laura; Günzl, Alexandra; Kehler, Patrik

Psyttala horrida (Stål, 1865) (Hemiptera: Reduviidae: Reduviinae)-A Morphological Study of Eggs and Nymphs

Psyttala horrida (Stål, 1865)(半翅目:Reduviidae:Reduviinae)-卵和若虫的形态学研究

Bugaj-Nawrocka, Agnieszka; Danielczyk, Agata; Sułkowska, Iga; Chłond, Dominik

Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas

托莫妥昔单抗(一种针对表皮生长因子受体的糖基化治疗性抗体)在晚期癌患者中的I期研究

Fiedler, Walter; Cresta, Sara; Schulze-Bergkamen, Henning; De Dosso, Sara; Weidmann, Jens; Tessari, Anna; Baumeister, Hans; Danielczyk, Antje; Dietrich, Bruno; Goletz, Steffen; Zurlo, Alfredo; Salzberg, Marc; Sessa, Cristiana; Gianni, Luca

Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours

TrasGEX(一种糖基化优化的抗HER2单克隆抗体)在HER2阳性实体瘤患者中的I期研究

Fiedler, Walter; Stoeger, Herbert; Perotti, Antonella; Gastl, Guenther; Weidmann, Jens; Dietrich, Bruno; Baumeister, Hans; Danielczyk, Antje; Goletz, Steffen; Salzberg, Marc; De Dosso, Sara

Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts

糖基化工程化的抗人程序性死亡配体1抗体比其正常的糖基化和非糖基化对应物更能激活CD8 T细胞

Christoph Goletz ,Timo Lischke ,Ulf Harnack ,Phillip Schiele ,Antje Danielczyk ,Johanna Rühmann ,Steffen Goletz

Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy

用于癌症免疫治疗的人类细胞系衍生的单克隆 IgA 抗体

Felix Hart, Antje Danielczyk, Steffen Goletz

Disorder-specific effects of polymorphisms at opposing ends of the Insulin Degrading Enzyme gene

胰岛素降解酶基因两端多态性对特定疾病的影响

Bartl, Jasmin; Scholz, Claus-Jürgen; Hinterberger, Margareta; Jungwirth, Susanne; Wichart, Ildiko; Rainer, Michael K; Kneitz, Susanne; Danielczyk, Walter; Tragl, Karl H; Fischer, Peter; Riederer, Peter; Grünblatt, Edna